Regeneron secures approval for ultra-rare bone disorder drug

Regeneron's therapy for an ultra-rare condition that causes abnormal bone formation has received U.S. regulatory approval. The decision ends a three-decade-long development effort for the company.

The approval marks the culmination of a research program that began roughly thirty years ago. The therapy addresses a rare genetic condition in which bone tissue develops in inappropriate locations within the body, a process that can progressively impair movement and function over time.

This decision adds to a growing category of treatments for orphan diseases, which affect very small patient populations. Drugmakers pursuing such therapies often face considerable hurdles, including limited clinical trial participants and uncertain commercial returns, making regulatory approvals of this kind particularly notable within the pharmaceutical industry.